Abstract. An 8-month-old female Great Pyrenees dog with chronic epistaxis and a history ofgingival bleeding during shedding of deciduous teeth was evaluated for platelet function. Platelet morphology was normal at both the light and electron microscopic level. Platelet number and mean platelet volume were also normal. Platelet aggregation responses to adenosine diphosphate, collagen, platelet activating factor, and thrombin were markedly reduced, although shape change responses were normal. Clot retraction was markedly impaired. Monoclonal protein electrophoresis. This is the first reported case of type I Glanzmann's thrombasthenia in the dog that closely resembles the clinical syndrome and the platelet morphology described in type I Glanzmann's thrombasthenia of human beings.
Materials and Methods

Patient
A female Great Pyrenees dog, born in January 1993, had excessive gingival bleeding during shedding of deciduous teeth between the ages of 3 and 6 months, requiring that the dog be hospitalized almost continuously. Shortly after the eruption of all permanent teeth, gingival bleeding ceased; however, epistaxis started shortly afterward and could not be curtailed. Blood work indicated that the dog was not thrombocytopenic and had a normal value for von Willebrand factor antigen (1 08%; reference range, 70-1 80%). Routine coagulation screening tests (activated partial thromboplastin time, prothrombin time, thrombin time) were normal. A female sibling, living in the same environment as the affected dog, did not have a bleeding diathesis. At the age of 8 months, the affected dog and sibling were referred to Auburn University for platelet function evaluation. The patient's platelets responded to adenosine diphosphate (ADP), collagen, and platelet activating factor (PAF) with shape change, but platelet aggregation was minimal; the change in light transmittance ranged from 1% to 7%. Clot retraction was markedly reduced. Platelet function in the sibling of the affected dog was enhanced as compared with that of a normal, nonrelated control dog, and clot retraction was normal. The af-Vet Pathol 335, 1996 fected dog was donated to Auburn University for further study; the sibling remained with the owners and was neutered without complication. The owners of the dam and sire of these dogs could not be located. During the ensuing 15 months, the affected dog continued to have epistaxis. Endoscopic and radiographic examinations failed to identify foreign bodies or anatomical malformations. Bleeding was diffuse in nature and appeared to originate from the nasal mucosa. Tranexarnic acid (250 mg) diluted in 2% lidocaine and deamino-8-D-arginine vasopressin (1 00 pg), given daily intranasally and independently for 1 week each failed to arrest or slow the bleeding. Iron was administered intramuscularly (50 mg twice daily) to maintain iron status; oral iron (324 mg once daily) was ineffective in maintaining iron stores. At age 23 months of age, spontaneous epistaxis ceased and iron supplementation was discontinued. As of this writing, petechial hemorrhages are evident sporadically on the gingiva and abdomen. Gingival bleeding can be induced if the dog is allowed to chew on rawhides; however, the bleeding is self-limiting. At 28 months of age, the dog experienced her first estrous cycle. Bleeding from the vulva was greater than normal and continued for 2 weeks. A slight anemia was present at the end o f the estrous cycle; however, iron supplementation was not necessary.
Platelet aggregation
Blood was collected into 3.8% trisodium citrate at a ratio o f 9 : 1. Platelet-rich plasma (PRP) was isolated via differential centrifugation at 21 C by spinning blood for three or four 2-minute intervals at 600-700 x g and pooling the serially collected supernatants. Platelet numbers and mean platelet volume were determined, and PRP concentration was adjusted to 300,0OO/pl using autologous platelet-poor plasma prior to study. Platelet aggregation was measured in a dual channel aggregometer (Model 450, Chrono-log Corp., Havertown, PA) equipped with a recorder (Model 707, Chrono-log Corp.). Platelet suspensions (450 PI) were stirred for 1 minute at 37 C prior to addition of agonist or control diluent.' In selected experiments, affected dog and normal dog platelets were pelleted (4,000 x g, 30 seconds, microcentrifuge Model 54 14, Eppendorf, Hamburg, Germany) and resuspended in normal dog plasma and affected dog plasma, respectively, prior to study. Similarly prepared normal and affected canine platelets resuspended in Tangen-HEPES buffer (147 mM NaCI, 5 mM KCI, 0.05 mM CaCI,, 0.1 mM MgCI,, 5 mM HEPES, 5.5 mM glucose, pH 7.4) were evaluated for response to bovine thrombin.
Platelet 14C-~er~tonin release
Platelet 14C-serotonin release was evaluated concurrently with platelet aggregation in selected experiments. PRP was radiolabeled at 21 C for 30 minutes by adding 2 pl of a I4C-serotonin stock solution (0.008 pCi/pl) per milliliter of PRP.5 Imipramine (3 pM final) was added to PRP at the conclusion of 30 minutes and just prior to evaluation. At the end of each aggregation study, 125 p1 ofcold formaldehyde (633 mM in 54 mM ethylenediaminetetraacetic acid [EDTAI-0.15 M NaC1) was added to the cuvette, and the cuvette was immediately immersed in ice. Cooled samples were spun immediately in an Eppendorf microcentrifuge for 1 minute at 16 ,000 x g, and duplicate 50-p1 aliquots of supernatant were removed for scintillation counting. Total platelet 14C-serotonin uptake was determined by evaluating samples of nonactivated whole PRP and PRP supernatant. Saline (0.85%) solution was used to determine 14C-serotonin release induced by stirring alone.
Clot retraction
Blood (0.5 ml) was drawn directly into a plastic syringe containing 4.5 ml of cold saline and mixed gently. Two milliliters of the mixture was added to each of two glass tubes containing 0.1 ml of 10 unitslml bovine thrombin (1 unit final). The tubes were mixed and capped and placed in a refrigerator for 30 minutes. After 30 minutes, the tubes were transferred to a 37 C water bath. The degree ofclot retraction was recorded after 1 and 2 hours as 1 + (minimal) to 4+ (maximal). Samples obtained from the affected dog were always evaluated concurrently with samples obtained from a normal dog.
Flow cytometry
Blood was collected into 3.8% trisodium citrate at a ratio of 9 : 1. PRP was isolated, and 10-pl aliquots were added to IOO-pI aliquots of buffer (10 mM HEPES, 145 mM NaCI, 1 mM MgSO,, pH 7.4). Monoclonal antibodies were added to samples of diluted PRP. For antibodies directly labeled with fluorescein isothiocyanate (FITC) an isotype control antibody was used as a control for nonspecific fluorescence. For the assays in which a secondary FITC-labeled antibody was added for detection, secondary antibody was added alone in control experiments. In selected experiments, dithiothreitol was added to expose fibrinogen receptors prior to addition of antibody. The fluorescent signal to noise ratio (FSN) in test samples was calculated using a computer program 
Immunoradiometric assay
Affected and control platelets were washed three times in phosphate-buffered saline (PBS) with 3% bovine serum albumin (BSA) and l pM prostaglandin (PG) El. Washed platelets were resuspended in PBS/BSA and tested in duplicate with canine plasma containing anti-glycoprotein Ib activity,33 normal control canine plasma, human plasma containing anti-PIA1 activity,32 and normal control human plasma. Twenty microliters of each test plasma was incubated for 1 hour at 37 C with 1.5 x lo7 platelets in 130 pl PBWBSA. The platelets were then washed three times, each time with 1 ml of 37 C PBS/BSA. The platelets were resuspended in 150 pl of PBS/BSA containing 10 ng of 12SI-labeled staphylococcal protein A (SPA). After a 1 hour incubation at room temperature, the unbound SpA was removed with three 1 -ml washes with PBS/BSA. The platelets were resuspended and transferred to tubes for measuring the platelet-associated radioactivity in a gamma counter. Platelet-associated radioactivity was reported as the percentage of added radioactivity remaining with the platelets (Yo bound).
Electron microscopy
Samples of PRP were diluted 50% with 0.1% glutaraldehyde. Platelets were sedimented (1 6,000 x g, 1 minute, Eppendorf microcentrifuge), the supernatant was removed, and 3% glutaraldehyde was added to the pellet. Samples were agar embedded in 1% SeaPlaque (FMC Marine Colloids, Rockland, ME), postfixed in 1% osmium tetraoxide, dehydrated in a graded series ofethanols, and embedded in Spurr's resin. Ultrathin sections were stained with uranyl acetate and lead citrate and were examined with a Philips 301 electron microscope (Philips Electronic Instruments, Norcross, GA).
Protein electrophoresis
Blood (1 00 ml) was drawn from a normal dog, from the affected dog, and from a normal human being into 1.5% EDTA (final concentration). PRP was isolated, and after addition of PGE, (3.0 pM final), platelets were washed three times with Tangen-HEPES buffer. The final platelet pellets were resuspended in 2 ml Tangen-HEPES buffer, and the samples were counted. The platelets were repelleted and resuspended in 1% sodium dodecyl sulfate (SDS), 5% p-mercaptoethanol, 0.06 M Tris (pH 6.8), and 25% v/v glycerol to a final concentration of 5 x lo6 platelets/pl. For nonreduced samples, P-mercaptoethanol was eliminated. Samples were boiled for 5 minutes and centrifuged at 10,000 x g for 5 minutes, and supernatants were frozen in aliquots at -80 C.
One hundred micrograms of platelet protein (reduced and nonreduced samples either done separately or separated by protein standards) in 50-pl aliquots was loaded per lane of a 5-1 5% gradient gel. After electrophoresis, separated platelet proteins and molecular weight standards were stained with Coomassie blue or were transferred to polyvinylidene difluoride membrane (PVDF; Millipore Corp., Bedford, MA). PVDF membranes were blocked with casein and incubated overnight with primary antibodies in the cold. Membranes were washed repeatedly with PBS. Alkaline phosphataseconjugated goat affinity-purified F(ab'), fragments to mouse IgG (Cappel, Durham, NC) were added and incubated for a minimum of 90 minutes. Color development was achieved using a kit (Bio-Rad, Hercules, CA). Primary antibodies eval-
anti-human platelet glycoprotein allb (SZ22, AMAC, Westbrook, ME), and CAP1 (anti-RIBS on canine fibrin~gen).~ For two dimensional protein electrophoresis of 12sI-surface-labeled platelet membrane glycoproteins, 50 ml of EDTA-anticoagulated blood was collected from the patient and a normal dog. PRP was isolated and washed three times after addition of PGE,. The final platelet pellets were resuspended in PBS containing 1 mM EDTA and 2% BSA for transport to the Michigan State University laboratory. Upon arrival (within 12 hours), test and control platelets were washed three times with EDTA-PBS (EPS [pH 7.21; 1 mM EDTA, 154 mM NaCl, 18 mM phosphate) to remove BSA. For each sample, 200 pl of 1 mg/ml lactoperoxidase (Sigma Chemical Co., St. Louis, MO) in PBS, pH 7.2, and 0.4 mCi lZsI (NaI, NEN Dupont) was added to 1 x lo9 platelets in 800 p1 EPS. To this reaction mixture was added 50 pl of 3 mM H,O, in 10-p1 aliquots, with gentle mixing for 10 seconds between additions. The reaction mixtures were diluted to 4 ml with EPS, and free Iz5I was removed by washing three more times with 4 ml EPS per wash using 10-minute centrifugations at 2,000 x g for pelleting. Washed pellets were resuspended in 200 pl nonreducing SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer (0.1 M Tris [pH 6.81, 3 .3% SDS, 16.7% glycerol, bromphenol blue). Two-dimensional nonreduced-reduced SDS-PAGE (modified rnethod3O with discontinuous buffer system2,) was performed. The stacking gels were 4% (w/v) acrylamide for both dimensions, and the resolving gels were 5% and 7% acrylamide for the first and second dimensions, respectively. For the first dimension, each sample was loaded at 3 x lo8 counts/minute per lane and electrophoresed overnight at 5 mA current. Lanes were cut from the first-dimension gel and incubated for 1 hour in reducing buffer consisting of 4% P-mercaptoethanol, 370 mM Tris (pH 6.8), and 0.1% SDS. The first-dimension gel lanes were then placed horizontally over the second-dimension gels, and the samples were electrophoresed simultaneously overnight at 5 mA per gel. Molecular weight standards were electrophoresed with each gel and visualized with Coomassie blue R. After staining, gels were dried for autoradiography.
Results
Platelet aggregation and release
Platelet aggregation in PRP samples obtained from the affected dog was markedly impaired in response to A D P , collagen, PAF, and thrombin. Epinephrine failed to potentiate platelet responses (Table 1) . Resuspension of affected dog platelets in normal canine citrated plasma failed to correct defective platelet aggregation responses; resuspension of normal dog platelets in affected dog plasma did n o t impair normal dog platelet aggregation responses (data not shown). ADP-induced platelet 14C-serotonin release was increased moderately in the affected dog and markedly in the sibling compared with that observed in a normal control. T h r o mbin-a n d PAF-induced platelet 14C-~er~tonin release in the affected dog samples were comparable to slightly diminished in comparison with that observed in the normal control; however, collagen-induced serotonin release was markedly diminished. A shape change response was documented in response to all agonists tested with the exception of epinephrine, which did not induce a shape change response in normal canine platelets.
Clot retraction
Clot retraction was markedly reduced in the affected dog and was recorded a s 1 + after 1 and 2 hours of observation. (Fig. 1) . The normal control samples and the samples obtained from the affected dog's sibling, were recorded as 3 + after 1 hour and as 4+ after 2 hours. markedly reduced compared with binding to normal canine platelets ( Table 3 ).
Electron microscopy electron microscopic level.
Protein electrophoresis and immunoblotting
The number of protein bands present in Coomassiestained SDS-polyacrylamide gels of whole platelet proteins precluded discernment of gross differences bePlatelet morphology was normal at the light and tween affected and normal canine platelets. Normal human platelet proteins were electrophoresed simultaneously, and differences in band migration patterns were observed when comparing canine and human samples.
Immunoblots of platelet proteins were more helpful in discerning differences among human, normal canine, and affected canine platelet samples. MoAb Y21 5 1 bound to a distinct band of approximately 100 kd in the nonreduced normal dog platelet preparation and to a band of 95-105 kd in the nonreduced normal Anti-P 1 7 37 Human control plasma human platelet sample (Fig. 3) . MoAb Y2/51 did not detectably bind to affected dog platelet samples. MoAb CAPl bound to nonreduced canine fibrinogen in both the normal and affected dog platelet samples; however, binding to affected dog platelets was diminished compared with binding in the normal canine platelet sample (Fig. 4) . MoAb CAPl did not bind to normal human platelet fibrinogen. MoAb SZ22, against human platelet q I b , bound to human platelet samples at a band of 145 kd. MoAb SZ22 did not bind to normal or affected canine platelet samples (data not shown). Two-dimensional electrophoresis of 1251-surface-labeled platelet membrane glycoproteins indicated comparable amounts of Iba, Ia, and IIa in both the normal dog and the affected dog samples (Fig. 5) . Although prominent spots were present in the normal dog sample corresponding to IIba, IIbp, and IIIa, these glycoproteins were markedly reduced to absent in the affected dog sample. Fibrinogen bands were present on the gel of the control dog but not on the gel of the affected dog after 3-day exposures. Similarly, on Coomassiestained two-dimensional gels, which assessed cytosolic, granular, and membrane proteins, fibrinogen bands were obvious for the control sample but were faint for the affected dog sample.
Discussion
Glanzmann's thrombasthenia is a rare inherited intrinsic platelet defect in which the IIb-IIIa glycoprotein complex, also known as the fibrinogen receptor and as the integrin unit O(IIb&, is either reduced or qualitatively altered. 15,28.30,38 In human beings, GT is an autosomal recessive defect and occurs more frequently in families where consanguinity is common. GT has been diagnosed most frequently in Israel, Jordan, South India, and France; most patients are diagnosed prior to 5 years of age, usually during infancy.I5 The most consistent clinical manifestations of disease include purpura, epistaxis, gingival hemorrhage, and menorrhagia. Spontaneous epistaxis is common in affected children but becomes less frequent as they become young adults. In this report, the platelet defect of this Great Pyrenees dog closely resembled that described as type I GT in human beings. Platelet numbers and morphology were normal; however, platelet aggregation responses and clot retraction were markedly reduced. Flow cytometric and 1251-surface-labeling experiments verified a marked reduction in integrin subunits aIlb and p3. Other surface proteins, including glycoprotein Ib, were not reduced. Immunoradiometric experiments using antibodies against glycoprotein Ib and PIAl further supported these observations. PIA1 is an alloantigen present on glycoprotein IIIa of human and canine platelet^;^^.^^ therefore, reduction of this antigen is supportive of a reduction in the p3 subunit.
Platelet fibrinogen levels were reduced in affected dog platelets, in agreement with findings in human beings with type I GT and supporting the importance of the integrin aIIbP3 in endocytosis of fibrinogen by platelets.'* The overall marked increase in platelet reactivity in the sibling may have been related to endogenous epinephrine release. Platelet studies were performed the morning after arrival of the dogs from Mississippi and after the two dogs had spent the night in a new environment separated from their owners and handled by unfamiliar human beings. Because the sibling was taken back home the same day, this premise could not be verified in repeat experiments. In repeat experiments conducted on the platelets from the affected dog, ADPinduced 14C-~er~tonin release continued to be moderate to high, and collagen-and PAF-induced release continued to be low. Platelet aggregation consistently remained markedly reduced. In most normal dogs, ADP, even at concentrations as high as 100 pM, does not induce significant platelet 14C-~er~tonin release (<5'/0). However, one of the authors (M. K. Boudreaux) has evaluated ADP-induced aggregation and release in over 100 dogs and has observed that as many as 10% ofnormal dogs have platelets that release > 10% I4C-serotonin in response to 25 The affected and sibling dogs in this study did not have heartworm disease; therefore, they may represent a subpopulation of dogs with enhanced ADP-induced 14C-~er~tonin release. In human beings with GT, ADP-induced 14C-~er~tonin release is normal.39 Reduced collagen-induced serotonin release in affected canine platelets is similar to that seen in human GT23 and in Basset Hound thrombopathia" and suggests that platelet-platelet interactions may be important for mediating release by this agonist. PAF-induced serotonin release may also require platelet-platelet interactions.
Boudreaux, Kvam, Dillon, Bourne, Scott, Schwartz, and Toivio-I(lnnucan Vet Pathol 3 3 5 , 1996 Thrombasthenic thrombopathia of Otterhounds is the intrinsic platelet defect most similar to type I GT previously described in dog^.^^.^^ Thrombasthenic thrombopathia, however, differs from GT of human beings in that 30-80% of the platelet population consists of bizarre giant forms similar in morphology to those observed with Bernard-Soulier syndrome. Also, in this defect glycoprotein Ib is increased compared with that in normal canine platelets, and glycoprotein IIb is variably reduced. Basset Hound thrombopathia and Spitz thrombopathia are possible examples of variant G T that have been described in d o g~.~,~J~J~ However, further characterization of these defects at the gene level is necessary to verify this possibility.
The clinical presentation of the Great Pyrenees described in this report closely matches the clinical syndrome described in human beings with type I GT.I5 Epistaxis was a chronic clinical manifestation until the dog attained the age of 23 months, i.e., young adulthood. At this writing, gingival hemorrhage still occurs with trauma associated with chewing rawhide; however, bleeding is self-limiting. Petechial hemorrhages are commonly observed on the buccal mucosa and sporadically on the abdomen. The dog is small for the breed, approximately 65 pounds, and this stunting may be attributed to enhanced iron demands during growth. At presentation upon referral, serum iron levels were undetectable and the patient was severely anemic. Iron, administered intramuscularly until the dog was 18 months old, was necessary to correct and prevent return of iron deficiency. Oral iron was ineffective in preventing iron deficiency until the dog's iron demands for growth had diminished.
Menorrhagia is a common problem in women with type I GT. Dogs do not slough their endometrium during estrus; loss of blood from the uterus is due to diapedesis secondary to vascular e n g~r g e m e n t .~~ Considering this species difference, estrus may be better tolerated in canine G T than menstruation is tolerated in women with GT. Recent studies at the molecular level have demonstrated that type I G T in human beings can result from a variety of defects in the genes for glycoproteins IIb or IIIa.6,9J2,20,25,37 Information at the gene level is vital for future studies evaluating gene therapy for the treatment of severe GT in human beings. Canine models for the hemophilias have proven valuable in studies of gene therapy and should be considered as potential models in treatment of GT. Minimal to no information is presently available on the genes for glycoproteins IIb or IIIa in the dog. Presumably these genes in the dog would share some homology with the genes in the mouse and human being. Future studies in the dog should focus on determining molecular variants associated with clinically significant platelet defects versus variants associated with benign polymorphisms. Evaluation of the genetic basis for the defects in Basset Hound thrombopathia and Otterhound thrombasthenic thrombopathia, in which numerous animals have been identified and for which the inheritance patterns are known, should be significant first steps. Determination of the genetic basis for the defect in this Great Pyrenees and continued evaluation and genetic documentation of recognized platelet function defects will add vital information to the field and position veterinary researchers as central players in future plateletgene therapy research.
